Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in HFpEF with Type 2 Diabetes Mellitus
ChiCTR2600130443Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Aug 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4, randomised trial of semaglutide in heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Composite endpoints (cardiovascular death or hospitalization for heart failure). Planned start Aug 2026; status: not yet recruiting.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600130443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600130443.